US EditionPublished • loading... • Updated
Argentines Created a Biotechnology Platform Against Cancer and Licensed It for $12.5 Million
Summary by El Cronista
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
The company Unleash Immuno Oncolytics, founded by entrepreneur Daniel Katzman, signed an international agreement for about $12.5 million to license its technology to the US TransCode Therapeutics, which will now be in charge of bringing these developments to clinical and, eventually, commercial instances. Katzman explained to El Cronista, the agreement - free of royalties and completely paid- was “an efficient way to capture value today and tran…
·Argentina
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
